Over the past 10 to 15 years, the availability of new materials and technologies has resulted in revolutionary concepts for contact lenses being proposed that go well beyond correcting vision. These novel uses include their prescribing to deliver topical ocular and systemic drugs, assist with ocular surface disease management, and limit the progression of myopia and novel methods to display visual information. How likely are these concepts to become commercially available, how successful will they be, and what are the potential issues to consider for them to come to market? To answer these questions, a panel of four experts were invited to discuss the benefits and pitfalls of these technologies and what challenges lay ahead of these concepts before their availability.
View Article and Find Full Text PDFBackground: This paper examines the potential impact of recruitment source differences in schizophrenia research by comparing the neuropsychological performance of volunteers from the NISAD Schizophrenia Research Register with recently published schizophrenia normative data for the Repeatable Battery for Neuropsychological Status (RBANS).
Methods: The Register sample comprised 285 volunteers with schizophrenia or schizoaffective disorder. Their RBANS performance was compared with US data from 575 predominantly outpatient-recruited schizophrenia patients.
Background: This study is a followup to a previous study in which the optics of several progressive addition lens (PALs) designs were measured and analyzed. The objective was to provide information about various PAL designs to enable eye care practitioners to select designs based on the particular viewing requirements of the patient.
Methods: The optical properties of 12 lenses of the same power for each of 23 different PAL designs were measured with a Rotlex Class Plus lens analyzer.